Analysts Issue Forecasts for Alector FY2026 Earnings

Key Points

• HC Wainwright forecasts Alector will earn $0.80 per share in FY2026, compared with the current consensus estimate of a $0.55-per-share loss, and maintains a Strong Buy rating.
• The firm projects losses to return from FY2027 through FY2030, forecasting annual EPS between a $0.52 and $0.72 loss.
• Analyst views are mixed: MarketBeat reports an overall Hold rating and an average price target of $4.62; Alector reported quarterly EPS of $1.11, beating the consensus estimate of a $0.23 loss.

Alector, Inc. (NASDAQ:ALEC - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for shares of Alector in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of $0.80 for the year. HC Wainwright currently has a "Strong-Buy" rating on the stock. The consensus estimate for Alector's current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Alector's Q4 2026 earnings at $0.12 EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.58) EPS, FY2029 earnings at ($0.72) EPS and FY2030 earnings at ($0.52) EPS.

Other equities research analysts have also issued reports about the stock. UBS Group reiterated a "neutral" rating and set a $1.50 price target on shares of Alector in a research note on Tuesday, October 6th. Wall Street Zen upgraded shares of Alector from a "hold" rating to a "buy" rating in a research note on Saturday. Weiss Ratings upgraded Alector from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. Finally, Morgan Stanley lifted their target price on Alector from $2.00 to $3.00 and gave the stock an "underweight" rating in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $4.62.

Alector Trading Up 7.4%

Shares of Alector stock opened at $2.46 on Tuesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26. The company has a fifty day simple moving average of $2.06 and a 200-day simple moving average of $2.04. Alector has a 12-month low of $1.09 and a 12-month high of $2.76.

Alector (NASDAQ:ALEC - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $1.34. The business had revenue of $162.87 million during the quarter, compared to the consensus estimate of $2.19 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%.

Insider Activity

In related news, CFO Neil Berkley sold 29,251 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the transaction, the chief financial officer directly owned 350,649 shares of the company's stock, valued at $932,726.34. This represents a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Arnon Rosenthal sold 72,606 shares of Alector stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $193,131.96. Following the completion of the sale, the chief executive officer owned 2,294,600 shares in the company, valued at approximately $6,103,636. This trade represents a 3.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 111,303 shares of company stock worth $295,633 in the last 90 days. 8.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alector

A number of hedge funds and other institutional investors have recently bought and sold shares of ALEC. Russell Investments Group Ltd. boosted its position in shares of Alector by 8.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 106,614 shares of the company's stock worth $197,000 after purchasing an additional 8,118 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Alector in the 2nd quarter valued at about $8,679,399. Public Employees Retirement System of Ohio purchased a new position in shares of Alector in the 2nd quarter valued at about $241,000. Bank of America Corp DE acquired a new stake in shares of Alector in the second quarter valued at about $287,000. Finally, Elmind Capital LP acquired a new stake in shares of Alector in the second quarter valued at about $1,809,000. Institutional investors and hedge funds own 85.83% of the company's stock.

Alector News Summary

Here are the key news stories impacting Alector this week:

• Positive Sentiment: HC Wainwright forecasts EPS of $0.80 for FY2026, including $0.12 in Q4, versus the current full-year consensus estimate of a $0.55 loss. The firm’s Strong-Buy rating may bolster investor sentiment.
• Negative Sentiment: The analyst expects losses to resume: EPS forecasts are ($0.61) for FY2027, ($0.58) for FY2028, ($0.72) for FY2029, and ($0.52) for FY2030. These projections temper the near-term optimism.

About Alector

Alector, Inc NASDAQ: ALEC is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's research platform, known as immuno-neurology, is designed to use the body's immune system to protect or restore the brain's ability to maintain healthy neural connections.

Alector's investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer's disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.